MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 11-05-2025
Charles River Laboratories International Total Assets 2011-2025 | CRL
Total Assets — these are all the resources owned by the business that have economic value. They are used to operate the business, generate profit, and ensure the company’s stability.Main categories of assets
Current assets (used within one year):
- Cash and cash equivalents
- Accounts receivable (amounts owed by customers)
- Inventory of goods, raw materials, and supplies
- Short-term investments
- Fixed assets (buildings, machinery, equipment)
- Intangible assets (brands, patents, software)
- Long-term investments
- Goodwill (reputational value from mergers)
Assets represent an objective measure of a business's value, reflecting everything behind it: physical infrastructure, technology, customer base, and financial resources. A high share of liquid assets such as cash indicates a company’s financial flexibility and its ability to maintain stability in changing market conditions.
Asset analysis helps assess how effectively a company utilizes its resources to generate revenue and profit, reflecting its operational efficiency and ability to convert invested capital into financial results.
Annual Total Assets Charles River Laboratories International
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 7.53 B | 8.2 B | 7.6 B | 7.02 B | 5.49 B | 4.69 B | 3.86 B | 2.93 B | 2.71 B | 2.07 B | 1.89 B | 1.64 B | 1.59 B | 1.56 B |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 8.2 B | 1.56 B | 4.2 B |
Quarterly Total Assets Charles River Laboratories International
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 7.51 B | 7.56 B | 7.58 B | 7.53 B | 8 B | 7.95 B | - | 8.2 B | 7.61 B | 7.77 B | 7.7 B | 7.6 B | 7.38 B | - | 7.08 B | 7.02 B | 7.06 B | 6.72 B | 5.81 B | 5.49 B | 5.49 B | 5.49 B | 5.49 B | 4.69 B | 4.69 B | 4.69 B | 4.69 B | 3.86 B | 3.86 B | 3.86 B | 3.86 B | 2.93 B | 2.93 B | 2.93 B | 2.93 B | 2.71 B | 2.71 B | 2.71 B | 2.71 B | 2.07 B | 2.07 B | 2.07 B | 2.07 B | 1.87 B | 1.88 B | 1.88 B | 1.89 B | 1.63 B | 1.63 B | 1.63 B | 1.63 B | 1.59 B | 1.59 B | 1.59 B | 1.59 B | 1.56 B | 1.56 B | 1.56 B | 1.56 B |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 8.2 B | 1.56 B | 4.21 B |
Total Assets of other stocks in the Diagnostics research industry
| Issuer | Total Assets | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Akumin
AKU
|
1.77 B | - | -17.87 % | $ 25.9 M |  Canada |
|
Centogene N.V.
CNTG
|
77.2 M | - | -6.23 % | $ 30.6 M |  Germany |
 |
Brainsway Ltd.
BWAY
|
94.3 M | $ 19.29 | -1.73 % | $ 99.4 M |  Israel |
 |
Chembio Diagnostics
CEMI
|
62.6 M | - | 0.22 % | $ 16.8 M |  USA |
 |
Castle Biosciences
CSTL
|
531 M | $ 40.09 | -0.27 % | $ 1.11 B | USA |
 |
Burning Rock Biotech Limited
BNR
|
2.28 B | $ 21.26 | -2.34 % | $ 229 M |  China |
 |
Accelerate Diagnostics
AXDX
|
65 M | - | -61.36 % | $ 2.46 M | USA |
 |
Biocept
BIOC
|
30.9 M | - | -13.05 % | $ 7.29 M | USA |
 |
DarioHealth Corp.
DRIO
|
96.4 M | $ 10.04 | -0.99 % | $ 285 M | Israel |
 |
Enzo Biochem
ENZ
|
85.8 M | - | -8.98 % | $ 14.8 K | USA |
 |
BioNano Genomics
BNGO
|
76.7 M | $ 1.52 | -0.65 % | $ 1.93 M | USA |
 |
Danaher Corporation
DHR
|
77.5 B | $ 231.47 | 0.28 % | $ 169 B | USA |
 |
Exact Sciences Corporation
EXAS
|
5.93 B | $ 101.54 | -0.05 % | $ 18.8 B | USA |
 |
DexCom
DXCM
|
6.26 B | $ 67.42 | 0.84 % | $ 26 B | USA |
 |
Oxford Immunotec Global PLC
OXFD
|
235 M | - | - | $ 562 M |  Britain |
 |
HTG Molecular Diagnostics
HTGM
|
17.8 M | - | -20.0 % | $ 1.06 M | USA |
 |
Fulgent Genetics
FLGT
|
1.22 B | $ 27.01 | -0.55 % | $ 817 M | USA |
 |
Global Cord Blood Corporation
CO
|
8.53 B | - | - | $ 399 M | China |
 |
Fluidigm Corporation
FLDM
|
325 M | - | 1.08 % | $ 308 M | USA |
 |
Genetic Technologies Limited
GENE
|
20.8 M | - | - | $ 7.1 B |  Australia |
 |
Genetron Holdings Limited
GTH
|
975 M | - | 0.12 % | $ 80.1 M | China |
 |
DermTech
DMTK
|
122 M | - | -11.32 % | $ 2.94 M | USA |
 |
PRA Health Sciences, Inc.
PRAH
|
4.18 B | - | - | $ 10.7 B | USA |
 |
CareDx, Inc
CDNA
|
467 M | $ 19.73 | -1.45 % | $ 1.06 B | USA |
 |
Celcuity
CELC
|
245 M | $ 102.61 | 0.25 % | $ 4.05 B | USA |
 |
Anixa Biosciences
ANIX
|
21.6 M | $ 3.42 | 3.64 % | $ 109 K | USA |
 |
Co-Diagnostics
CODX
|
95.3 M | $ 0.24 | -1.79 % | $ 7.04 M | USA |
 |
IQVIA Holdings
IQV
|
26.9 B | $ 226.02 | 0.39 % | $ 41 B | USA |
 |
Motus GI Holdings
MOTS
|
7.22 M | - | -34.28 % | $ 263 K | Israel |
 |
Guardant Health
GH
|
1.49 B | $ 102.38 | -0.12 % | $ 12.6 B | USA |
 |
NeoGenomics
NEO
|
1.64 B | $ 12.3 | -0.97 % | $ 1.56 B | USA |
 |
Neogen Corporation
NEOG
|
3.44 B | $ 7.14 | -0.14 % | $ 1.55 B | USA |
 |
Aspira Women's Health
AWH
|
17.4 M | - | -6.19 % | $ 10.5 M | USA |
 |
National Research Corporation
NRC
|
122 M | $ 18.81 | -1.05 % | $ 462 M | USA |
 |
Heska Corporation
HSKA
|
586 M | - | - | $ 1.31 B | USA |
 |
OPKO Health
OPK
|
2.2 B | $ 1.3 | -0.76 % | $ 902 M | USA |
 |
Organovo Holdings
ONVO
|
14.6 M | - | -2.3 % | $ 19.4 M | USA |
 |
OpGen
OPGN
|
9.86 M | - | -16.95 % | $ 1.54 M | USA |
 |
Pacific Biosciences of California
PACB
|
1.75 B | $ 1.88 | 3.3 % | $ 477 M | USA |
 |
Mettler-Toledo International
MTD
|
3.24 B | $ 1 417.16 | 0.18 % | $ 30.1 B |  Schweiz |
 |
Illumina
ILMN
|
6.3 B | $ 135.32 | -0.64 % | $ 21.5 B | USA |
 |
ENDRA Life Sciences
NDRA
|
4.45 M | $ 5.1 | - | $ 2.74 M | USA |
 |
Koninklijke Philips N.V.
PHG
|
29 B | $ 26.98 | 0.37 % | $ 20 B |  Niderland |
 |
Personalis
PSNL
|
270 M | $ 8.41 | -0.12 % | $ 498 M | USA |
 |
PerkinElmer
PKI
|
12.4 B | - | -0.91 % | $ 14.7 B | USA |
 |
Quidel Corporation
QDEL
|
1.87 B | $ 28.91 | 1.12 % | $ 1.22 B | USA |
 |
Quest Diagnostics Incorporated
DGX
|
16.2 B | $ 175.92 | 0.48 % | $ 19.5 B | USA |
|
Biodesix
BDSX
|
97.2 M | $ 6.82 | 1.04 % | $ 884 M | USA |
 |
Precipio
PRPO
|
18.1 M | $ 23.89 | 2.56 % | $ 31 M | USA |